| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/23/2006 | CA2580534A1 4-((phenoxyalkyl)thio)-phenoxyacetic acid derivatives and use thereof as ppar modulators |
| 03/23/2006 | CA2580491A1 4-((phenoxyalkyl)thio)-phenoxyacetic acid derivatives and use thereof as ppar modulators |
| 03/23/2006 | CA2580460A1 Combination of polychitosamine and hmg-coa reductase inhibitor for hyperlipidemia |
| 03/23/2006 | CA2580457A1 Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
| 03/23/2006 | CA2580409A1 Triazole derivative or salt thereof |
| 03/23/2006 | CA2580347A1 Halogenated benzamide derivatives |
| 03/23/2006 | CA2580343A1 Imidazoquinoline compounds |
| 03/23/2006 | CA2580330A1 A controlled slow release formulation of thiamine and use thereof in the treatment of pathologies connected to defective process of learning and memorization |
| 03/23/2006 | CA2580292A1 Process for preparing substituted 8-azabicyclo[3.2.1] octan-3-ols |
| 03/23/2006 | CA2580286A1 Dermally applicable formulations for treating skin diseases in animals |
| 03/23/2006 | CA2580264A1 Long acting injectable crystal formulations of estradiol metabolites and methods of using same |
| 03/23/2006 | CA2580251A1 Substituted bicyclic imidazo-3-yl-amine compounds |
| 03/23/2006 | CA2580236A1 Purinenucleoside derivative modified in 8-position and medical use thereof |
| 03/23/2006 | CA2580202A1 Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy |
| 03/23/2006 | CA2580135A1 7-azaindoles and their use as ppar agonists |
| 03/23/2006 | CA2580131A1 Substituted aniline derivatives |
| 03/23/2006 | CA2580078A1 Compounds, compositions and methods for controlling biofilms and bacterial infections |
| 03/23/2006 | CA2580076A1 Betulinol derivatives as anti-hiv agents |
| 03/23/2006 | CA2580033A1 Imidazole compound |
| 03/23/2006 | CA2580020A1 Aryl spirolactam cgrp receptor antagonists |
| 03/23/2006 | CA2579964A1 Composition with preventive or improvement effect on stress-induced brain function impairment and related symptoms or diseases |
| 03/23/2006 | CA2579923A1 Anti-parasitic and/or anti-viral and/or anti-microbial compositions |
| 03/23/2006 | CA2579851A1 Use of uridine for improving cognitive and neurological functions |
| 03/23/2006 | CA2579850A1 Tricyclic anilide spirohydantoin cgrp receptor antagonists |
| 03/23/2006 | CA2579847A1 Bicyclic anilide spirolactam cgrp receptor antagonists |
| 03/23/2006 | CA2579807A1 Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders |
| 03/23/2006 | CA2579784A1 Topical compositions containing phosphorylated polyphenols |
| 03/23/2006 | CA2579717A1 Tricyclic anilide spirolactam cgrp receptor antagonists |
| 03/23/2006 | CA2579514A1 Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (sarms) |
| 03/23/2006 | CA2579501A1 Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient |
| 03/23/2006 | CA2579490A1 Therapeutic agent for keratoconjunctiva disorder |
| 03/23/2006 | CA2579476A1 Thiazolinone 4-monosubstituted quinolines |
| 03/23/2006 | CA2579472A1 Hydrazone derivatives and their use as beta secretase inhibitors |
| 03/23/2006 | CA2579348A1 Thiazolinone 2-substituted quinolines |
| 03/23/2006 | CA2579177A1 A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
| 03/23/2006 | CA2579143A1 Vanilloid receptor ligands and their use in treatments |
| 03/23/2006 | CA2579130A1 Substituted hydantoins for the treatment of cancer |
| 03/23/2006 | CA2579121A1 Process for production of optically active amine derivatives |
| 03/23/2006 | CA2578355A1 Methods of treating a disorder |
| 03/23/2006 | CA2578248A1 Multiple sclerosis treatment |
| 03/23/2006 | CA2577258A1 Biotinylated hexadecasaccharides, their preparation and their use as anticoagulants and antithrombotics of heparin |
| 03/23/2006 | CA2577024A1 Methods of treating proliferative skin diseases using carbazole derivatives |
| 03/23/2006 | CA2576294A1 Novel 3-methyl-7-butinyl-xanthines, production thereof, and use thereof as medicaments |
| 03/23/2006 | CA2576057A1 Mitotic kinesin inhibitors |
| 03/23/2006 | CA2575788A1 Combination of pkc activators and pkc inhibitors for alzheimer's diseasetreatment and cognitive enhancement |
| 03/23/2006 | CA2568832A1 Indole derivatives as antiviral agents |
| 03/22/2006 | EP1637611A1 Method for producing oligosaccharides |
| 03/22/2006 | EP1637608A2 Recombinant adenoviral vector and methods of use |
| 03/22/2006 | EP1637602A1 Recombinant method for preparing of a complete malaria antigen gp190/msp1 |
| 03/22/2006 | EP1637592A1 Neuronal progenitor cells, methods to produce them and uses thereof for the therapy of neural defects |
| 03/22/2006 | EP1637539A1 Pyrazole derivative, drug composition containing the same and production intermediate therefor |
| 03/22/2006 | EP1637537A1 New medicaments |
| 03/22/2006 | EP1637533A1 Substituted thiazolopyrimidines as analgetics |
| 03/22/2006 | EP1637529A1 Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof |
| 03/22/2006 | EP1637528A1 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease |
| 03/22/2006 | EP1637527A1 Cannabinoid receptor modulator |
| 03/22/2006 | EP1637522A1 Substituted pyrazoline compounds for reducing triglycerides in blood |
| 03/22/2006 | EP1637519A1 Crystalline forms of the sodium salt of 5-chloro-2-methoxy-N-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonylphenyl)ethyl)benzamide |
| 03/22/2006 | EP1637518A2 Inhibitors of aspartyl protease |
| 03/22/2006 | EP1637516A1 Sertraline hydrochloride polymorphs |
| 03/22/2006 | EP1637515A1 Sertraline hydrochloride polymorphs |
| 03/22/2006 | EP1637170A1 Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
| 03/22/2006 | EP1637167A2 New injectable formulations containing progesterone |
| 03/22/2006 | EP1637164A2 Improved formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| 03/22/2006 | EP1637161A1 REMEDY FOR CEREBRAL NEURODEGENERATIVE DISEASES USING PPAR&dgr; AGONIST |
| 03/22/2006 | EP1637158A2 Capsular polysaccharide immunomodulator |
| 03/22/2006 | EP1637157A1 Pharmaceutical composition for the treatment of pelvic pain |
| 03/22/2006 | EP1637156A1 Systemic administration of osteogenic proteins in the treatment of metabolic bone diseases |
| 03/22/2006 | EP1637152A1 A notoginseng saponin intravenous injection and the method for preparing this injection |
| 03/22/2006 | EP1637151A1 Preventive or remedy for arthritis |
| 03/22/2006 | EP1637144A1 Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite |
| 03/22/2006 | EP1637143A1 Sulfacetamide formulations further containing a sunscreen for treatment of rosacea |
| 03/22/2006 | EP1637142A2 Stable solid formulation of enalapril salt and process for preparation thereof |
| 03/22/2006 | EP1637141A1 Stabilized protease composition comprising a serine protease, morpholino derivatives and reversible inhibitors of said serine protease |
| 03/22/2006 | EP1637140A1 Use of diphenylmethylpiperazine derivatives for the manufacture of a medicament for suppressing the proliferation of fibroblasts |
| 03/22/2006 | EP1637139A2 Novel use of HIV protease inhibiting compounds |
| 03/22/2006 | EP1637138A2 Use of thiazolidinediones to prevent or delay onset of NIDDM |
| 03/22/2006 | EP1637137A2 Method and composition for administering a cyclooxygenase-2 inhibitor to animals |
| 03/22/2006 | EP1637136A1 Composition having autonomic nerve modulating activity and method of use thereof |
| 03/22/2006 | EP1637135A1 Compositions comprising dimethylsulfoxide and tretinoin for treating skin disorders |
| 03/22/2006 | EP1637134A1 Composition for prevention/treatment for varicose veins |
| 03/22/2006 | EP1637133A2 Use of 2,5-dihydroxybenzenesulfonic acid derivatives for the preparation of medicaments for normalising the endothelial function, for the treatment of sexual dysfunction and vascular complications of diabetes, and vascular disorders of endothelial origin |
| 03/22/2006 | EP1637132A1 External preparation for athlete´s foot treatment |
| 03/22/2006 | EP1637129A1 Composition comprising alfuzosin |
| 03/22/2006 | EP1637126A2 Methods for treating inflammation of the eye |
| 03/22/2006 | EP1636592A1 Use of prion conversion modulating agents |
| 03/22/2006 | EP1636585A2 Diaryl ureas with kinase inhibiting activity |
| 03/22/2006 | EP1636385A2 Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo |
| 03/22/2006 | EP1636335A2 Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase |
| 03/22/2006 | EP1636279A1 Poly and copoly (n -vinylamide)s and their use in capillary electrophoresis |
| 03/22/2006 | EP1636249A1 Target-oriented chemotherapy for treating tumors of the sexual organs |
| 03/22/2006 | EP1636240A1 Beta-lactamase inhibitor prodrug |
| 03/22/2006 | EP1636238A1 Heteroryl-fused pyrimidinyl compounds as anticancer agents |
| 03/22/2006 | EP1636236A1 Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors |
| 03/22/2006 | EP1636233A1 Cannabinoid receptor ligands and uses thereof |
| 03/22/2006 | EP1636232A2 Immunosuppressive effects of pteridine derivatives |
| 03/22/2006 | EP1636230A2 A1 adenosine receptor antagonists |
| 03/22/2006 | EP1636229A2 A1 adenosine receptor antogonists |
| 03/22/2006 | EP1636228A1 Novel pyridopyrazines and use thereof as kinase modulators |
| 03/22/2006 | EP1636227A1 Pyrimidine derivatives possessing cell-cycle inhibitory activity |